Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 9Completed 9Withdrawn 6Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 62Squamous Cell Carcinoma of Head and Neck 46Breast Neoplasms 37Neoplasm Metastasis 34Parkinson Disease 4, Autosomal Dominant Lewy Body 32Carcinoma, Renal Cell 30Lung Neoplasms 29Colorectal Neoplasms 29Neoplasms 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 22Head and Neck Neoplasms 22Stomach Neoplasms 17Urinary Bladder Neoplasms 16Endometrial Neoplasms 15Carcinoma, Transitional Cell 15Pancreatic Neoplasms 13Prostatic Neoplasms 11Uterine Cervical Neoplasms 10Sarcoma 10Esophageal Neoplasms 10Small Cell Lung Carcinoma 9Recurrence 9Glioblastoma 8Fallopian Tube Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma 8Skin Neoplasms 7Oropharyngeal Neoplasms 7

Interventions

Dexamethasone 115Lenalidomide 74daratumumab 57Bortezomib 52carfilzomib 41Calcium Dobesilate 36pomalidomide 35Cyclophosphamide 26isatuximab 23belantamab mafodotin 22Specimen Handling 20Biopsy 20Magnetic Resonance Spectroscopy 17dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 12ixazomib 11iberdomide 11fludarabine 11elotuzumab 11selinexor 10Melphalan 10fludarabine phosphate 8talquetamab 7X-Rays 7trametinib 6nirogacestat 6venetoclax 5Thalidomide 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Multiple Myeloma × pembrolizumab × Clear all
NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡